AnalystsGeorge ZavoicoGeorge Zavoico's Stock Forecasts
AnalystsGeorge Zavoico
Sectors:
Industries:
Analyst Ranking
Top 30%
#1459 out of 4872 analysts
Average Return
+12.86%
Win Rate
55%6 out of 11
Risk vs Reward
Poor
Good
George Zavoico's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Arqule IncARQL | +118.71% | $1.55 | $3.39 | 2018-02-12 - 2019-02-12 | Strong Buy |
Arqule IncARQL | +99.10% | $5.53 | $11.01 | 2018-06-29 - 2019-06-28 | Strong Buy |
Novavax IncNVAX | +65.89% | $25.80 | $42.80 | 2018-01-05 - 2019-01-04 | Strong Buy |
Gyre Therapeutics IncGYRE | +37.53% | $113.10 | $155.55 | 2017-12-08 - 2018-06-21 | Strong Buy |
Biolife Solutions IncBLFS | +16.41% | $13.89 | $16.17 | 2018-10-03 - 2019-10-03 | Strong Buy |
George Zavoico Analyst Color
Get additional color on George Zavoico's coverage of popular stocks
George Zavoico's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Novavax IncNVAX | 3 | Strong Buy | $35.00 | N/A | Maintains | 6 years ago |
Biolife Solutions IncBLFS | 1 | Strong Buy | $22.00 | N/A | Maintains | 7 years ago |
Cellular Biomedicine Group IncCBMG | 1 | Strong Buy | $38.00 | N/A | Maintains | 7 years ago |
Actinium Pharmaceuticals IncATNM | 2 | Strong Buy | $90.00 | N/A | Maintains | 7 years ago |
Arqule IncARQL | 2 | Strong Buy | $7.50 | N/A | Maintains | 7 years ago |
Gyre Therapeutics IncGYRE | 3 | Hold | $12.50 | N/A | Downgrades | 7 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.